Partner Headlines - ALKS

  1. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  2. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  3. Alkermes pops to 15-year high

    IBD
  4. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  5. Morning Market Gainers

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Benzinga's Volume Movers

    Benzinga
  8. 3 Biotech ETFs Rally On Merger News

    Benzinga
  9. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  10. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  11. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  12. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  13. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  14. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  15. Alkermes' drug passes trial

    IBD
  16. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  17. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  18. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  19. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  20. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  21. Benzinga's Volume Movers

    Benzinga
  22. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  23. Morning Market Movers

    Benzinga
  24. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  25. Benzinga's Top Initiations

    Benzinga
  26. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  27. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  28. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  29. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  30. Stocks End Short Week With Big Losses

    IBD
  31. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  32. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  33. Ireland Home To Several Fast Growing Health Care Names

    IBD
  34. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  35. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  36. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  37. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  38. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  39. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  40. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  41. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  42. Alkermes

    IBD
  43. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  44. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  45. Alkermes

    IBD
  46. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  47. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  48. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  49. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  50. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  51. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  52. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  53. Stocks Pare Early Losses, End With Modest Declines

    IBD
  54. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  55. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  56. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  57. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  58. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  59. Dow Leads Market Higher As Volume Swells

    IBD
  60. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  61. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  62. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  63. Stocks Tumble On Disappointing Earnings Reports

    IBD
  64. Why Cisco, Google And Apple All Became Big Winners

    IBD
  65. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  66. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  67. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  68. Alkermes Writes New Prescription For Growth

    IBD
  69. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  70. Health Care Sector Wrap

    FoxBusiness
  71. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  72. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  73. Elan

    IBD
  74. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  75. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  76. Market Roundup

    Benzinga
  77. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  78. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  79. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  80. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  81. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  82. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  83. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  84. Benzinga's Top Pre-Market Gainers

    Benzinga
  85. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  86. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  87. Benzinga's Volume Gainers

    Benzinga
  88. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  89. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  90. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  91. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  92. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center